Q1 2020 13F Holders as of 3/31/2020
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
56.1M
-
Number of holders
-
64
-
Total shares
-
22.3M
-
Shares change
-
+22.3M
-
Total reported value, excl. options
-
$555M
-
Value change
-
+$555M
-
Number of buys
-
64
-
Price
-
$24.95
Significant Holders of Black Diamond Therapeutics, Inc. - Common Stock (BDTX) as of Q1 2020
64 filings reported holding BDTX - Black Diamond Therapeutics, Inc. - Common Stock as of Q1 2020.
Black Diamond Therapeutics, Inc. - Common Stock (BDTX) has 64 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 22.3M shares
of 56.1M outstanding shares and own 39.74% of the company stock.
Largest 10 shareholders include NEA Management Company, LLC (3.45M shares), RA CAPITAL MANAGEMENT, L.P. (2.59M shares), BOXER CAPITAL, LLC (2.01M shares), Artal Group S.A. (1.7M shares), FMR LLC (1.59M shares), Bellevue Group AG (1.33M shares), WELLINGTON MANAGEMENT GROUP LLP (1.26M shares), PERCEPTIVE ADVISORS LLC (1.1M shares), VANGUARD GROUP INC (633K shares), and DRIEHAUS CAPITAL MANAGEMENT LLC (583K shares).
This table shows the top 64 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.